Cystic fibrosis heterozygotes do not have increased platelet activation

Research output: Contribution to journalJournal articleResearchpeer-review

Inge Tarnow, Alan D. Michelson, Andrew L. Frelinger III, Matthew D. Linden, Youfu Li, Marsha L. Fox, Marc R. Barnard, Brian P. O'Sullivan

Introduction: We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF m utation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.
Materials and methods: We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.
Results: We found no difference in platelet activation between CF heterozygotes and controls.
Conclusions: The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.
Original languageEnglish
JournalThrombosis Research
Issue number2
Pages (from-to)159-162
Number of pages4
Publication statusPublished - 2007

    Research areas

  • LIFE - Platelets, Cystic fibrosis, Flow cytometry, Cystic fibrosis carriers, Platelet function

ID: 8094892